Volume 29, issue 11, October 2022

149 articles in this issue

1. GLOBOCAN 2020 Report on Global Cancer Burden: Challenges and Opportunities for Surgical Oncologists

2. Sequencing of Therapies in Progressive Neuroendocrine Tumors

3. Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations

4. Neoadjuvant Chemotherapy for Breast Cancer: The Ultimate “Spy”

5. Editorial: Updating the Operative Standards for Cancer Surgery Key Questions

6. Synoptic Operative Reports: Can Form Follow Function in Surgery?

7. Opportunities and Challenges of Defining “Value” in Oncology Care

8. Disparities in Time to Treatment for Breast Cancer: Shifting Focus to the Root Cause

9. Assessing the Role of 3D Vision Technology for Laparoscopy

10. Editorial Perspective: Robot-Assisted Evaluation of Robotic Surgical Skills

11. Technical Standards for Cancer Surgery: Improving Patient Care through Synoptic Operative Reporting

12. ASO Author Reflections: Surgeons Adding Value—Are Synoptic Operative Reports a Step Forward in Cancer Care?

13. ASO Visual Abstract: Technical Standards for Cancer Surgery—Improving Patient Care through Synoptic Operative Reporting

14. What is “Value”? Results of a Survey of Cancer Patients and Providers

15. ASO Author Reflections: Can We Measure ‘Value’?

16. ASO Visual Abstract: What is “Value”? Results of a Survey of Cancer Patients and Providers

17. Technical Standards for Cancer Surgery: Commission on Cancer Standards 5.3–5.8

18. ASO Author Reflections: Technical Standards for Cancer Surgery: From “How I Do It” to “How We Do It”

19. Oncologic Components of HIPEC: Key Question

20. ASO Visual Abstract: Oncologic Components of HIPEC—Key Question

21. Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Versus Metachronous Onset of Peritoneal Metastases of Colorectal Carcinoma

22. ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

23. ASO Visual Abstract: Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Versus Metachronous Onset of Peritoneal Metastases of Colorectal Carcinoma

24. Systemic Chemotherapy for High-Grade Mucinous Appendiceal Cancer with Peritoneal Spread After Unsuccessful CRS/HIPEC

25. ASO Author Reflections: CRS/HIPEC Cannot be Done—Now what? Systemic Chemotherapy in Mucinous Appendiceal Cancer

26. ASO Visual Abstract: Systemic Chemotherapy in High-Grade Mucinous Appendiceal Cancer with Peritoneal Spread after Unsuccessful Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)

27. Socioeconomic Barriers to CRS HIPEC for Appendiceal Cancer within a Regional Academic Hospital System

28. ASO Author Reflections: Understanding Barriers to Complex Cancer Surgery

29. ASO Visual Abstract: Socioeconomic Barriers to CRS HIPEC for Appendiceal Cancer within a Regional Academic Hospital System

30. Rethinking Routine Intensive Care After Cytoreductive Surgery With Heated Intraperitoneal Chemotherapy: The Fiscal Argument

31. ASO Author Reflections: An Opportunity to Provide Cost-Conscious Care for Patients Undergoing CRS-HIPEC

32. ASO Visual Abstract: Rethinking Routine Intensive Care After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy: The Fiscal Argument

33. The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-Analysis

34. ASO Author Reflections: Neoadjuvant Systemic Chemotherapy in Isolated Resectable Colorectal Peritoneal Metastases: Ready for Standard of Care?

35. Surgery Refusal Among Black and Hispanic Women with Non-Metastatic Breast Cancer

36. ASO Author Reflections: Surgery Refusal in Breast Cancer Has a Disproportionate Impact on Black and Hispanic Women

37. Surgical and Oncologic Outcomes of Robotic and Conventional Nipple-Sparing Mastectomy with Immediate Reconstruction: International Multicenter Pooled Data Analysis

38. ASO Visual Abstract: Surgical and Oncologic Outcomes of Robotic and Conventional Nipple-Sparing Mastectomy with Immediate Reconstruction—International Multicenter Pooled Data Analysis

39. Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated?

40. ASO Author Reflections: Sentinel Lymph Node Biopsy in BRCA1/2 Germline Pathogenic Variant Carriers Undergoing Risk-Reducing Mastectomy

41. ASO Visual Abstract: Incidence of Occult Breast Cancer in Carriers of BRCA1/2 and Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy–When is Sentinel Lymph Node Biopsy Indicated?

42. Surgical Management and Contralateral Breast Cancer Risk in Women with History of Radiation Therapy for Hodgkin Lymphoma: Results from a Population-Based Cohort

43. Modified Radical Mastectomy in De Novo Stage IV Inflammatory Breast Cancer

44. ASO Author Reflections: Surgical Management Should be Considered in Patients with De Novo Stage IV Inflammatory Breast Cancer

45. ASO Visual Abstract: Modified Radical Mastectomy in De Novo Stage IV Inflammatory Breast Cancer

46. Racial Disparities in Time to Treatment Persist in the Setting of a Comprehensive Breast Center

47. ASO Author Reflections on “Racial Disparities in Time to Treatment Persist in the Setting of a Comprehensive Breast Center”

48. ASO Visual Abstract: Racial Disparities in Time to Treatment Persist in the Setting of a Comprehensive Breast Center

49. How Much Pain Will I Have After Surgery? A Preoperative Nomogram to Predict Acute Pain Following Mastectomy

50. ASO Visual Abstract: How Much Pain Will I Have After Surgery? A Preoperative Nomogram to Predict Acute Pain Following Mastectomy

51. Dual-Layer Rotation: A Versatile Therapeutic Mammoplasty Technique

52. ASO Visual Abstract: Dual-Layer Rotation: A Versatile Therapeutic Mammoplasty Technique

53. Access to Surgical Treatment for Breast Cancer in the Philippines

54. Impact of Three-Dimensional (3D) Visualization on Laparoscopic Hepatectomy for Hepatocellular Carcinoma

55. Impact of Preoperative CEA Uptrend on Survival Outcomes in Patients with Colorectal Liver Metastasis After Hepatectomy

56. ASO Author Reflections: CEA Uptrend is a Useful Biomarker to Predict Post-Hepatectomy Survival Outcomes in Patients with Colorectal Liver Metastasis

57. ASO Visual Abstract: Impact of Preoperative CEA Uptrend on Survival Outcomes in Patients with Colorectal Liver Metastasis after Hepatectomy

58. Does Caudate Resection Improve Outcomes of Patients Undergoing Curative Resection for Perihilar Cholangiocarcinoma? A Systematic Review and Meta-Analysis

59. ASO Visual Abstract: Does Caudate Resection Improve Outcomes inPatients Undergoing Curative Resection forPerihilar Cholangiocarcinoma? ASystematic Review and Meta-analysis

60. Application of a Convolutional Neural Network for Multitask Learning to Simultaneously Predict Microvascular Invasion and Vessels that Encapsulate Tumor Clusters in Hepatocellular Carcinoma

61. ASO Visual Abstract: Application of a Convolutional Neural Network for Multitask Learning to Simultaneously Predict Microvascular Invasion and Vessels That Encapsulate Tumor Clusters in Hepatocellular Carcinoma

62. Radiomics-Based Preoperative Prediction of Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma Using Contrast-Enhanced Computed Tomography

63. ASO Author Reflections: Radiomics-Based Strategy of Combining Conventional Clinico-Radiological Characteristics with Preoperative Prediction of Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma

64. ASO Visual Abstract: Radiomics-Based Preoperative Prediction of Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma Using Contrast-Enhanced Computed Tomography

65. Patterns of Caudate Lobe Invasion of Hilar Cholangiocarcinoma: A Panoramic Histologic Study of Liver

66. ASO Author Reflections: Panoramic Histologic Patterns of Caudate Lobe Invasion in Hilar Cholangiocarcinoma

67. Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses

68. ASO Visual Abstract: Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial embolization: A Retrospective Study on Patterns, Treatments, and Prognosis

69. Long-Term Outcomes of Perioperative Versus Neoadjuvant Chemotherapy for Resectable Colorectal Liver Metastases: An International Multicentre Propensity-Score Matched Analysis with Stratification by Contemporary Risk-Scoring

70. ASO Author Reflections: Peri-operative Chemotherapy for Resectable Colorectal Liver Metastases

71. ASO Visual Abstract: Long-Term Outcomes of Perioperative versus Neoadjuvant Chemotherapy for Resectable Colorectal Liver Metastases—An International Multicenter Propensity-Score Matched Analysis with Stratification by Contemporary Risk Scoring

72. Automated Surgical-Phase Recognition for Robot-Assisted Minimally Invasive Esophagectomy Using Artificial Intelligence

73. ASO Author Reflections: Can Artificial Intelligence Evaluate the Surgical Learning Curve of Robot-Assisted Minimally Invasive Esophagectomy?

74. ASO Visual Abstract: Automated Surgical Phase Recognition for Robot-Assisted Minimally Invasive Esophagectomy Using Artificial Intelligence

75. Albumin and Derived Neutrophil-to-Lymphocyte Ratio is a Novel Prognostic Factor for Patients with Esophageal Squamous Cell Carcinoma

76. ASO Author Reflections: Decrease of Albumin and Derived Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy Reflect the Worse Prognosis in Patients with Esophageal Squamous Cell Carcinoma

77. ASO Visual Abstract: Albumin and Derived Neutrophil-To-Lymphocyte Ratio is a Novel Prognostic Factor for Patients with Esophageal Squamous Cell Carcinoma

78. Impact of Body Mass Index and Sarcopenia on Short- and Long-Term Outcomes After Esophageal Cancer Surgery: An Observational Study

79. ASO Author Reflections: Impact of Body Mass Index and Sarcopenia on Short- and Long-term Outcomes after Esophageal Cancer Surgery

80. ASO Visual Abstract: Impact of Body Mass Index and Sarcopenia on Short- and Long-Term Outcomes After Esophageal Cancer Surgery—An Observational Study

81. Does Preoperative Corticosteroid Administration Improve the Short-Term Outcome of Minimally Invasive Esophagectomy for Esophageal Cancer? A Propensity Score-Matched Analysis

82. Elevation of the Prognostic Factor Plasma Fibrinogen Reflects the Immunosuppressive Tumor Microenvironment in Esophageal Squamous Cell Carcinoma

83. ASO Author Reflections: Does Elevation of the Prognostic Factor Plasma Fibrinogen Level Reflect the Tumor Microenvironment at the Primary Site?

84. ASO Visual Abstract: Elevation of the Prognostic Factor Plasma Fibrinogen Reflects the Immunosuppressive Tumor Microenvironment in Esophageal Squamous Cell Carcinoma

85. Time to Incurable Recurrence for Patients Treated With Pulmonary Metastasectomy for Colorectal Cancer

86. ASO Author Reflections: New Indicator to Demonstrate Cure Probability: Time to Incurable Recurrence

87. ASO Visual Abstract: Time to Incurable Recurrence for Patients Who Receive Pulmonary Metastasectomy for Colorectal Cancer

88. Clinical Impact of Sarcopenia 1 Year After Surgery for Patients with Early-Stage Non-small Cell Lung Cancer

89. ASO Author Reflections: Management to Prevent Postoperative Sarcopenia in Patients with Lung Cancer

90. ASO Visual Abstract: Clinical Impact of Sarcopenia 1 Year after Surgery in Patients with Early-Stage Non-small Cell Lung Cancer

91. Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?

92. ASO Visual Abstract: Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?

93. Safety and Outcomes of Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine Tumors

94. ASO Author Reflections: Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine Tumors—A Single Operation is Feasible in Most Patients

95. ASO Visual Abstract: Safety and Outcomes of Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine Tumors

96. Effect of Chemoradiotherapy on the Survival of Resectable Gastric Cancer Patients: A Systematic Review and Meta-Analysis

97. ASO Author Reflections: Chemoradiotherapy Versus Chemotherapy, Which One Is Better for Resectable Gastric Cancer Patients?

98. ASO Visual Abstract: Effect of Chemoradiotherapy on the Survival of Resectable Gastric Cancer Patients—A Systemic Review and Meta-analysis

99. Management of Malignant Small Bowel Obstruction: Is Intestinal Bypass Effective Palliation?

100. ASO Author Reflections: Bypassing the Problem: Approaches for the Treatment of Malignant Small Bowel Obstruction

101. ASO Visual Abstract: Management of Malignant Small Bowel Obstruction—Is Intestinal Bypass Effective Palliation?

102. Recursive Partitioning to Determine Order of Significance of Regional Metastasis Characteristics in Head and Neck Cutaneous Squamous Cell Carcinoma

103. ASO Visual Abstract: Recursive Partitioning to Determine Order of Significance of Regional Metastasis Characteristics in Head and Neck Cutaneous Squamous Cell Carcinoma

104. Team-Based Surgical Scheduling for Improved Patient Access in a High-Volume, Tertiary Head and Neck Cancer Center

105. ASO Visual Abstract: Team-Based Surgical Scheduling for Improved Patient Access in a High-Volume, Tertiary Head and Neck Cancer Center

106. Correction to: Outcomes Following Percutaneous Microwave and Cryoablation of Lung Metastases from Adenoid Cystic Carcinoma of the Head and Neck: A Bi-Institutional Retrospective Cohort Study

107. Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration

108. ASO Visual Abstract: Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma—An International Multi-institutional Collaboration

109. Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases

110. ASO Author Reflections: What Is the Role of Surgery in Management of In-Transit Melanoma in the Modern Era?

111. ASO Visual Abstract: Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-transit Melanoma Metastases

112. An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma

113. ASO Visual Abstract: An Internally Validated Prognostic Risk Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma

114. Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail

115. ASO Author Reflections: Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail

116. ASO Visual Abstract: Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail

117. The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer

118. ASO Author Reflections: The Impact of CT-assessed Liver Steatosis on Postoperative Complications after Pancreaticoduodenectomy for Cancer

119. ASO Visual Abstract: The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer

120. Commentary on “Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer”

121. Response to: Commentary on: “Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer”

122. Comparison of Reconstruction Techniques Following Sacroiliac Tumor Resection: A Systematic Review

123. Sentinel Lymph Node Biopsy and Formal Lymphadenectomy for Soft Tissue Sarcoma: A Single Center Experience of 86 Consecutive Cases

124. ASO Author Reflections: Lymph Node Disease in Soft Tissue Sarcoma: A Problematic Clinical Dilemma

125. ASO Visual Abstract: Sentinel Lymph Node Biopsy and Formal Lymphadenectomy For Soft Tissue Sarcoma: A Single-Center Experience of 86 Consecutive Cases

126. Use of Neoadjuvant Imatinib to Facilitate Minimally Invasive Resection of Gastric Gastrointestinal Stromal Tumors

127. ASO Visual Abstract: Use of Neoadjuvant Imatinib to Facilitate Minimally Invasive Resection of Gastric Gastrointestinal Stromal Tumors

128. Feasibility of Preoperative Dose-Painting Intensity Modulated Radiation Therapy (IMRT) for Borderline-Resectable Primary Retroperitoneal Sarcoma

129. ASO Visual Abstract: Feasibility of Preoperative Dose-Painting Intensity-Modulated Radiation Therapy (IMRT) for Borderline Resectable Primary Retroperitoneal Sarcoma

130. Ten-Year Survivorship in Patients with Metastatic Gastrointestinal Stromal Tumors

131. ASO Visual Abstract: Ten-Year Survivorship in Patients with Metastatic Gastrointestinal Stromal Tumors

132. Correction to: Non-Private Health Insurance Predicts Advanced Stage at Presentation and Amputation in Lower Extremity High Grade Bone Sarcoma: A National Cancer Database Study

133. Versican Secreted by Cancer-Associated Fibroblasts is a Poor Prognostic Factor in Hepatocellular Carcinoma

134. ASO Visual Abstract: Versican Secreted by Cancer-Associated Fibroblasts Is a Poor Prognostic Factor in Hepatocellular Carcinoma

135. RAB11A Expression Is Associated With Cancer Aggressiveness Through Regulation of FGFR-Signaling in Lung Squamous Cell Carcinoma

136. ASO Visual Abstract: RAB11A Expression is Associated with Cancer Aggressiveness Through Regulation of FGFR-Signaling in Lung Squamous Cell Carcinoma

137. A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer

138. ASO Author Reflections: Deeper Insight into Therapeutic Implications and Non-invasive Detection of Homologous Recombination Deficiency in Triple-Negative Breast Cancer: Results from a Multi-omics Cohort Study

139. ASO Visual Abstract: A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer

140. Downregulation of ROBO4 in Pancreatic Cancer Serves as a Biomarker of Poor Prognosis and Indicates Increased Cell Motility and Proliferation Through Activation of MMP-9

141. ASO Author Reflections: Downregulation of ROBO4 in Pancreatic Cancer Serves as a Biomarker of Poor Prognosis and Indicates Increased Cell Motility and Proliferation Through Activation of MMP-9

142. ASO Visual Abstract: Downregulation of ROBO4 in Pancreatic Cancer Serves as a Biomarker of Poor Prognosis and Indicates Increased Cell Motility and Proliferation Through Activation of MMP-9

143. Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer

144. ASO Author Reflections: Inheritance of Adrenal Permissive HSD3B1 Genotype Negatively Impacts Outcomes in Hormone Receptor-Positive Postmenopausal Breast Cancer

145. ASO Visual Abstract: Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen Receptor-Positive Breast Cancer

146. Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data

147. ASO Visual Abstract: Anti-androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy—A Post Hoc Analysis of the RTOG 9601 Trial Data

148. Impact of Renal Cell Carcinoma Histological Variants on Recurrence After Partial Nephrectomy: A Multi-Institutional, Prospective Study (UROCCR Study 82)

149. ASO Visual Abstract: Impact of Renal Cell Carcinoma Histological Variants on Recurrence After Partial Nephrectomy: A Multi-institutional, Prospective Study (UROCCR Study 82)